Effect of Long-Term Metformin and Lifestyle in the Diabetes Prevention Program and Its Outcome Study on Coronary Artery Calcium

Circulation

Volumn 136, Issue 1, 2017, Pages 52-64

  Goldberg, Ronald B ^a,m   Aroda, Vanita R ^b   Bluemke, David A ^c   Barrett Connor, Elizabeth ^d   Budoff, Matthew ^e   Crandall, Jill P ^f   Dabelea, Dana ^g   Horton, Edward S ^h   Mather, Kieren J ⁱ   Orchard, Trevor J ^j   Schade, David ^k   Watson, Karol ^l   Temprosa, Marinella ^m  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b MedStar Health Research Institute Washington   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF COLORADO   (United States)

^h JOSLIN DIABETES CENTER   (United States)

ⁱ INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^k UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m GEORGE WASHINGTON UNIVERSITY   (United States)

more..

Author keywords

clinical trial publication type ; coronary artery disease; prediabetic state; therapeutics

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; PLACEBO; TISSUE PLASMINOGEN ACTIVATOR; ANTIDIABETIC AGENT; CALCIUM;

ADULT; AGATSTON SCORE; AGED; ARTICLE; BODY MASS; COHORT ANALYSIS; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY CALCIUM SCORE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC PATIENT; DIET RESTRICTION; DISEASE COURSE; DISEASE SEVERITY; ELECTROCARDIOGRAM; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HEALTH CARE PERSONNEL; HEALTH PROGRAM; HEART CYCLE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LONG TERM CARE; LOW CALORY DIET; LOW FAT DIET; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RISK FACTOR; WEIGHT REDUCTION; BLOOD; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG EFFECTS; LIFESTYLE; MIDDLE AGED; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; CALCIUM; CORONARY ARTERY DISEASE; CORONARY VESSELS; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; MALE; METFORMIN; MIDDLE AGED; TREATMENT OUTCOME;

EID: 85021773256     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.025483     Document Type: Article

References (36)

1. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215-2222.
2. Gregg EW, Li Y, Wang J, Burrows NR, Ali MK, Rolka D, Williams DE, Geiss L. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med. 2014;370:1514-1523.
3. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-1574.
4. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403. doi: 10.1056/NEJMoa012512.
5. Goldberg RB, Temprosa M, Haffner S, Orchard TJ, Ratner RE, Fowler SE, Mather K, Marcovina S, Saudek C, Matulik MJ, Price D; Diabetes Prevention Program Research Group. Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group. Diabetes Care. 2009;32:726-732. doi: 10.2337/dc08-0494.
6. Goldberg RB, Temprosa MG, Mather KJ, Orchard TJ, Kitabchi AE, Watson KE; Diabetes Prevention Program Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the Diabetes Prevention Program except in those who develop diabetes. Diabetes Care. 2014;37:2253-2260. doi: 10.2337/dc13-2471.
7. Detrano R, Guerci AD, Carr JJ, Bild DE, Burke G, Folsom AR, Liu K, Shea S, Szklo M, Bluemke DA, O'Leary DH, Tracy R, Watson K, Wong ND, Kronmal RA. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008;358:1336-1345. doi: 10.1056/NEJMoa072100.
8. Khaleeli E, Peters SR, Bobrowsky K, Oudiz RJ, Ko JY, Budoff MJ. Diabetes and the associated incidence of subclinical atherosclerosis and coronary artery disease: Implications for management. Am Heart J. 2001;141:637-644. doi: 10.1067/mhj.2001.113224.
9. American Diabetes Association. Standards of Medical Care in Diabetes - 2015: 2, classification and diagnosis of diabetes. Diabetes Care. 2015;38(suppl 1):S8-S16.
10. Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015;3:866-875.
11. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-612.
12. Carr JJ, Nelson JC, Wong ND, McNitt-Gray M, Arad Y, Jacobs DR Jr, Sidney S, Bild DE, Williams OD, Detrano RC. Calcified coronary artery plaque measurement with cardiac CT in population-based studies: standardized protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) study. Radiology. 2005;234:35-43. doi: 10.1148/radiol.2341040439.
13. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15:827-832.
14. Ma S, Liu A, Carr J, Post W, Kronmal R. Statistical modeling of Agatston score in Multi-Ethnic Study of Atherosclerosis (MESA). PLoS One. 2010;5:e12036. doi: 10.1371/journal.pone.0012036.
15. Marcus R, Peritz E, Gabriel KR. On closed testing procedures with special reference to ordered analysis of variance. Biometrika. 1976;63:655-660.
16. McClelland RL, Chung H, Detrano R, Post W, Kronmal RA. Distribution of coronary artery calcium by race, gender, and age: results from the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2006;113:30-37. doi: 10.1161/CIRCULATIONAHA.105.580696.
17. Bertoni AG, Wong ND, Shea S, Ma S, Liu K, Preethi S, Jacobs DR Jr, Wu C, Saad MF, Szklo M. Insulin resistance, metabolic syndrome, and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care. 2007;30:2951-2956. doi: 10.2337/dc07-1042.
18. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
19. Hong J, Zhang Y, Lai S, Lv A, Su Q, Dong Y, Zhou Z, Tang W, Zhao J, Cui L, Zou D, Wang D, Li H, Liu C, Wu G, Shen J, Zhu D, Wang W, Shen W, Ning G; SPREAD-DIMCAD Investigators. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2013;36:1304-1311. doi: 10.2337/dc12-0719.
20. Kooy A, de Jager J, Lehert P, Bets D, Wulffelé MG, Donker AJ, Stehouwer CD. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med. 2009;169:616-625. doi: 10.1001/archinternmed.2009.20.
21. Fitch K, Abbara S, Lee H, Stavrou E, Sacks R, Michel T, Hemphill L, Torriani M, Grinspoon S. Effects of lifestyle modification and metformin on atherosclerotic indices among HIV-infected patients with the metabolic syndrome. AIDS. 2012;26:587-597. doi: 10.1097/QAD.0b013e32834f33cc.
22. Preiss D, Lloyd SM, Ford I, McMurray JJ, Holman RR, Welsh P, Fisher M, Packard CJ, Sattar N. Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes Endocrinol. 2014;2:116-124. doi: 10.1016/S2213-8587(13)70152-9.
23. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol. 2001;37:1344-1350.
24. Goldberg R, Temprosa M, Otvos J, Brunzell J, Marcovina S, Mather K, Arakaki R, Watson K, Horton E, Barrett-Connor E. Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the Diabetes Prevention Program. J Clin Endocrinol Metab. 2013;98:3989-3998. doi: 10.1210/jc.2013-1452.
25. Vasamsetti SB, Karnewar S, Kanugula AK, Thatipalli AR, Kumar JM, Kotamraju S. Metformin inhibits monocyte-to-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation: potential role in atherosclerosis. Diabetes. 2015;64:2028-2041. doi: 10.2337/db14-1225.
26. Forouzandeh F, Salazar G, Patrushev N, Xiong S, Hilenski L, Fei B, Alexander RW. Metformin beyond diabetes: pleiotropic benefits of metformin in attenuation of atherosclerosis. J Am Heart Assoc. 2014;3:e001202. doi: 10.1161/JAHA.114.001202.
27. Cao X, Li H, Tao H, Wu N, Yu L, Zhang D, Lu X, Zhu J, Lu Z, Zhu Q. Metformin inhibits vascular calcification in female rat aortic smooth muscle cells via the AMPK-eNOS-NO pathway. Endocrinology. 2013;154:3680-3689. doi: 10.1210/en.2013-1002.
28. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S; Diabetes Prevention Program Research Group. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005;142:611-619.
29. Ozata M, Oktenli C, Bingol N, Ozdemir IC. The effects of metformin and diet on plasma testosterone and leptin levels in obese men. Obes Res. 2001;9:662-667. doi: 10.1038/oby.2001.90.
30. Vrbíková J, Hill M, Stárka L, Cibula D, Bendlová B, Vondra K, Sulcová J, Snajderová M. The effects of long-term metformin treatment on adrenal and ovarian steroidogenesis in women with polycystic ovary syndrome. Eur J Endocrinol. 2001;144:619-628.
31. Budoff MJ, McClelland RL, Nasir K, Greenland P, Kronmal RA, Kondos GT, Shea S, Lima JA, Blumenthal RS. Cardiovascular events with absent or minimal coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J. 2009;158:554-561. doi: 10.1016/j. ahj.2009.08.007.
32. American Diabetes Association. Standards of medical care in diabetes-prevention or delay of type 2 diabetes. Diabetes Care. 2015;38(suppl 1):S31-S32.
33. Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Haffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM. 10-Year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;14:1677-1686.
34. Lehmann N, Paul A, Moebus S, Budde T, Dobos GJ, Michalsen A. Effects of lifestyle modification on coronary artery calcium progression and prognostic factors in coronary patients: 3-year results of the randomized SAFELIFE trial. Atherosclerosis. 2011;219:630-636. doi: 10.1016/j.atherosclerosis. 2011.08.050.
35. Li G, Zhang P, Wang J, An Y, Gong Q, Gregg EW, Yang W, Zhang B, Shuai Y, Hong J, Engelgau MM, Li H, Roglic G, Hu Y, Bennett PH. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol. 2014;2:474-480. doi: 10.1016/S2213-8587(14)70057-9.
36. Puri R, Nicholls SJ, Shao M, Kataoka Y, Uno K, Kapadia SR, Tuzcu EM, Nissen SE. Impact of statins on serial coronary calcification during atheroma progression and regression. J Am Coll Cardiol. 2015;65:1273-1282. doi: 10.1016/j.jacc.2015.01.036.